PET imaging with F-18 fluorodeoxyglucose for primary lymphoma of bone

被引：17

作者：

Park, YH ^{[1
]}

Choi, SJ ^{[1
]}

Ryoo, BY ^{[1
]}

Kim, HT ^{[1
]}

机构：

[1] Korea Canc Ctr Hosp, Div Med Oncol, Dept Internal Med, Seoul 139706, South Korea

来源：

CLINICAL NUCLEAR MEDICINE | 2005年 / 30卷 / 02期

关键词：

primary bone lymphoma; FDG-PET;

D O I：

10.1097/00003072-200502000-00020

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Assessment of the response to therapy in patients with lymphoma involving bone can be difficult. In this patient, who demonstrated complete remission, the regions of fluorine-18 fluorodeoxyglucose (F-18 FDG) PET uptake diminished more rapidly after therapy, indicating a complete response at a much earlier stage than did magnetic resonance imaging (MRI)-based findings. With the MRI and computed tomography findings, it was difficult to assess whether the residual tumor tissue was viable. Serial studies using PET may be superior to MRI in the evaluation of primary lymphoma of bone (PLB).

引用

页码：131 / 134

页数：4

共 9 条

[1] Localized primary malignant lymphoma of bone [J].

Dubey, P ;

Ha, CS ;

Besa, PC ;

Fuller, L ;

Cabanillas, F ;

Murray, J ;

Hess, MA ;

Cox, JD .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (05) :1087-1093

[2] Malignant lymphoma of bone [J].

Dürr, HR ;

Müller, PE ;

Hiller, E ;

Maier, M ;

Baur, A ;

Jansson, V ;

Refior, HJ .

ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY, 2002, 122 (01) :10-16

[3] Primary non-Hodgkin's lymphoma of bone: a clinicopathology investigation of 60 cases [J].

Heyning, FH ;

Hogendoorn, PCW ;

Kramer, MHH ;

Hermans, J ;

Kluin-Nelemans, JC ;

Noordijk, EM ;

Kluin, PM .

LEUKEMIA, 1999, 13 (12) :2094-2098

[4] Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging [J].

Jerusalem, G ;

Beguin, Y ;

Fassotte, MF ;

Najjar, F ;

Paulus, P ;

Rigo, P ;

Fillet, G .

BLOOD, 1999, 94 (02) :429-433

[5]

Moog F, 1999, J NUCL MED, V40, P1407

[6] Imaging features of primary lymphoma of bone [J].

Mulligan, ME ;

McRae, GA ;

Murphey, MD .

AMERICAN JOURNAL OF ROENTGENOLOGY, 1999, 173 (06) :1691-1697

[7] Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma [J].

Naumann, R ;

Vaic, A ;

Beuthien-Baumann, B ;

Bredow, J ;

Kropp, J ;

Kittner, T ;

Franke, WG ;

Ehninger, G .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (04) :793-800

[8]

Römer W, 1998, BLOOD, V91, P4464

[9] Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma [J].

Spaepen, K ;

Stroobants, S ;

Dupont, P ;

Vandenberghe, P ;

Thomas, J ;

de Groot, T ;

Balzarini, J ;

De Wolf-Peeters, C ;

Mortelmans, L ;

Verhoef, G .

ANNALS OF ONCOLOGY, 2002, 13 (09) :1356-1363

← 1 →